TipRanks
Xilio Therapeutics (XLO)
NASDAQ:XLO
US Market
XLO
Xilio Therapeutics
RESEARCH TOOLSreports
Want to see XLO full AI Analyst Report?

Xilio Therapeutics (XLO) Income Statement

221 Followers

Xilio Therapeutics Income Statement

Last quarter (Q2 2026), Xilio Therapeutics's total revenue was $18.69M, an increase of 131.22% from the same quarter last year. In Q2, Xilio Therapeutics's net income was $-6.37M. See Xilio Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 43.77M$ 6.34M$ 0.00$ 0.00$ 0.00
Gross Profit
$ 42.23M$ 6.34M$ 0.00$ 0.00$ -1.50M
Operating Expenses
$ 84.21M$ 66.93M$ 79.13M$ 89.15M$ 73.55M
Depreciation and Amortization
$ 1.54M$ 1.64M$ 1.90M$ 1.85M$ 1.50M
EBITDA
$ -33.49M$ -58.00M$ -74.50M$ -86.38M$ -73.70M
Operating Income
$ -41.98M$ -60.58M$ -79.13M$ -89.15M$ -75.04M
Other Income/Expenses
$ 6.95M$ 2.34M$ 2.73M$ 927.00K$ -756.00K
Pretax Income
$ -35.04M$ -58.24M$ -76.40M$ -88.22M$ -75.80M
Net Income
$ -35.04M$ -58.24M$ -76.40M$ -88.22M$ -75.80M
Per Share Metrics
Basic EPS
$ -4.19$ -15.26$ -38.92$ -45.08$ -189.28
Diluted EPS
$ -4.19$ -15.26$ -38.92$ -45.08$ -189.28
Weighted Average Shares Outstanding
 8.36M 3.82M 1.96M 1.96M 400.45K
Weighted Average Shares Outstanding (Diluted)
 8.36M 3.82M 1.96M 1.96M 400.45K
Currency in USD

Xilio Therapeutics Earnings and Revenue History